Expertise in
9
conditions

Dr. Richard S. Hudes

Radiation Oncology
Chesapeake Urology Associates LLC
2 Park Ctr Ct, Suite 2, 
Owings Mills, MD 
Accepting New Patients
Offers Telehealth
Expertise in
9
conditions
Chesapeake Urology Associates LLC
2 Park Ctr Ct, Suite 2, 
Owings Mills, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Richard Hudes is a Radiation Oncologist in Owings Mills, Maryland. Dr. Hudes is highly rated in 9 conditions, according to our data. His top areas of expertise are Familial Prostate Cancer, Prostate Cancer, Intraductal Papilloma, and Lung Cancer. Dr. Hudes is currently accepting new patients.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in MD
Hospital Affiliations
Saint Agnes Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO

Locations

CHESAPEAKE UROLOGY ASSOCIATES LLC
2 Park Ctr Ct, Suite 2, Owings Mills, MD 21117
Other Locations
CHESAPEAKE UROLOGY ASSOCIATES LLC
3801 International Dr, Suite 310, Silver Spring, MD 20906
RADIATION ONCOLOGY HEALTHCARE, PA
900 Caton Ave, Baltimore, MD 21229

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: May 11, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 05, 2025
Intervention Type: Radiation
Study Phase: Phase 3
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction
RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction
Enrollment Status: Active_not_recruiting
Publish Date: January 17, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Radiation
Study Phase: Phase 3
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Enrollment Status: Unknown
Publish Date: June 12, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Etoposide, Carboplatin
Study Phase: Phase 3
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Enrollment Status: Unknown
Publish Date: May 24, 2022
Intervention Type: Drug, Procedure, Radiation
Study Drugs: mFOLFIRINOX, FOLFOX
Study Phase: Phase 2
View 8 Less Clinical Trials

9 Total Publications

Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926.
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 03, 2024
Similar Doctors
Expertise in
31
conditions
Dr. Lawrence R. Kleinberg
Radiation Oncology
Expertise in
31
conditions
Dr. Lawrence R. Kleinberg
Radiation Oncology

Johns Hopkins University

600 N Wolf St, 
Baltimore, MD 
 (11.1 mi)
410-955-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lawrence Kleinberg is a Radiation Oncologist in Baltimore, Maryland. Dr. Kleinberg is highly rated in 31 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Brain Tumor, Glioma, and Gamma Knife Radiosurgery. Dr. Kleinberg is currently accepting new patients.

Expertise in
18
conditions
Dr. Russell K. Hales
Radiation Oncology
Expertise in
18
conditions
Dr. Russell K. Hales
Radiation Oncology

Johns Hopkins University

600 N Wolf St, 
Baltimore, MD 
 (11.1 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Russell Hales is a Radiation Oncologist in Baltimore, Maryland. Dr. Hales is highly rated in 18 conditions, according to our data. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Thymic Epithelial Tumor, Orchiectomy, and Endoscopy. Dr. Hales is currently accepting new patients.

Expertise in
22
conditions
Dr. Harry C. Quon
Radiation Oncology
Expertise in
22
conditions
Dr. Harry C. Quon
Radiation Oncology

Johns Hopkins University

5215 Loughboro Rd Nw, Sibley Memorial Hospital, 
Washington, DC 
 (37.2 mi)
202-537-4000
Languages Spoken:
English
Accepting New Patients

Harry Quon is a Radiation Oncologist in Washington, Washington, D.c.. Dr. Quon is highly rated in 22 conditions, according to our data. His top areas of expertise are Laryngeal Cancer, Throat Cancer, Dry Mouth, Gastrostomy, and Prostatectomy. Dr. Quon is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hudes's expertise for a condition
ConditionClose
    View All 28 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile